Highest-materiality recent filing
Solésence to pay Refy £700,000 (~$938,000) in 12 monthly installments starting Aug 5, 2026.
Solésence Q1 revenue $13.0M (-11% YoY); net loss $0.8M vs prior-year profit
Revenue $13.0M vs $14.6M in Q1 2025; gross margin improved to 26% from 23%.
Solésence appoints Marc James as independent director to board and three committees
Marc James appointed as Class II Director effective April 24, 2026, term expires at 2026 Annual Meeting.
Solésence FY2025 rev $62.1M (+19%), net income drops to $1.8M from $4.2M
Full-year revenue $62.1M, up 19% YoY; net income $1.8M vs $4.2M in 2024.
Former CEO Jess Jankowski to receive $366,912 severance over 52 weeks plus accelerated vesting of all outstanding options.
Solesence: Jess Jankowski retires from board, enters consulting agreement; Cureton appointed
Jess Jankowski retired from Board effective Nov 21, 2025; CEO Kevin Cureton appointed to fill his Class III term.
Solésence Q3 revenue falls 14% YoY to $14.5M; net loss $1.1M vs prior-year profit
Revenue $14.5M vs $16.9M in Q3 2024; net loss $1.1M vs net income $3.0M.
Solésence settles product dispute with Solarium; $675,000 payment due by Jan 15, 2026
Settlement resolves disputes over skin care products Solésence manufactured for Solarium.
Solésence appoints Kevin Cureton as CEO, Laura Riffner as CFO; Jankowski advisor
Kevin Cureton, formerly COO, promoted to President and CEO effective Sept 3, 2025; base salary ≥ $367,000.
Solesence shareholders elect directors, approve 2025 equity plan, ratify RSM US LLP as auditor
Two director nominees elected: R. Janet Whitmore (55,548,531 votes for) and Laura M. Beres (55,853,069 votes for); broker non-votes 4,637,430.
Solésence Q2 revenue jumps 56% to $20.4M; net income $2.7M
Revenue of $20.4M vs $13.0M in Q2 2024, a 56% increase.
Solésence corrects certificate to add accent mark in company name
Filed certificate of correction on June 3, 2025 to add an accent over the first 'e' in Solésence.
Solésence increases debt facilities to $23M, extends maturity to April 2027
Amended three loan agreements with affiliates of controlling shareholder Bradford T. Whitmore on May 27, 2025.
Solésence reports record Q1 revenue $14.6M, up 48% YoY; net income breakeven vs $0.9M profit
Record Q1 revenue $14.6M, +48% YoY; gross margin 23% vs 36% due to one-time start-up costs.
Solesence announces uplisting to Nasdaq Capital Market, trading begins April 8 under ticker SLSN
Shares to trade on Nasdaq effective April 8, 2025; prior OTCQB ticker was NANX.
Solésence reports record full-year 2024 revenue of $52.3M, net income of $4.2M vs loss in 2023
Q4 revenue $12.6M (+57.5% YoY); gross profit $2.8M (22% margin) vs $0.5M (6%) in Q4 2023.
Nanophase Technologies changes name to Solesence, Inc. effective March 10, 2025
Name changed from Nanophase Technologies Corporation to Solesence, Inc. effective March 10, 2025.
Nanophase shareholders approve increase in authorized common stock from 60M to 95M shares
Shareholders at June 18, 2024 Special Meeting voted 39,837,787 for, 2,008,409 against to raise authorized shares from 60M to 95M.
Nanophase shareholders elect Jankowski and Miller as directors, ratify RSM US LLP as auditor
Jess A. Jankowski re-elected with 54,280,750 votes for, 34,768 withheld.
Nanophase reports record Q3 revenue $16.9M, net income $3M; Solésence revenue up 171%
Q3 revenue $16.9M (+112% YoY); net income $3.0M vs loss of $1.4M in Q3 2023.
Nanophase reports record Q2 revenue $13M (+10% YoY) and net income $856K (+157%)
Q2 revenue $13M vs $11.9M in Q2 2023 (+10%); Solésence revenue $11.2M (+44% YoY).
Nanophase reports record Q1 revenue $9.9M, net income $0.9M vs loss, BASF litigation resolved
Q1 revenue $9.9M (+4% YoY); net income $0.9M vs net loss of $1.2M in Q1 2023.
Nanophase settles BASF exclusivity litigation, amends supply agreement
Mutual release of all claims in BASF v. Nanophase (NJ Super. Ct. MRS-L-1396-22); case dismissed with prejudice.
Nanophase Q4/FY2023 revenue flat at $37.3M; net loss widens to $4.4M; secures $6M financing
Q4 revenue $8.0M (vs $8.3M YoY); full-year revenue $37.3M flat; net loss $4.4M ($0.09/sh) vs $2.6M in 2022.
Nanophase raises $6M in convertible preferred; Q4 revenue $8M, net loss $2.1M
Issued 15,000 Series X Preferred shares at $400 each to Strandler, LLC, affiliate of largest shareholder.
Nanophase withdraws 2023 profitability outlook; Q3 revenue hurt by supply chain issues
Nine-month revenue $29.3M vs $29.1M YoY; Q3 revenue down due to supply chain constraints.
Nanophase reports record Q2 revenue $11.9M, up 10% YoY; sees Q3 profit
Q2 revenue $11.9M (+10% product revenue YoY); H1 revenue $21.3M (+12% product revenue YoY)
Mark E. Miller appointed to Nanophase Board of Directors
Appointed as independent director effective July 19, 2023.
Nanophase posts record Q1 revenue of $9.5M, up 16% YoY; gross margin improves 4%
Q1 2023 revenue $9.5M vs $8.2M in Q1 2022, a 16% increase.
Nanophase enters $1.75M note with affiliate of majority shareholder for Bolingbrook facility
Borrowed $1.75M non-revolving line of credit from Beachcorp, LLC (affiliate of majority owner Bradford T. Whitmore) at Prime + 0.75%.
Nanophase reports record FY2022 revenue $37.3M (+27% YoY) but net loss of $2.6M
FY2022 revenue $37.3M, up 27% YoY; Q4 revenue $8.3M, up 12% YoY.
Nanophase Q3 revenue up 22% to $9.7M; reports $0.75M loss from costs and cyber theft
Q3 2022 revenue $9.7M (+22% YoY); nine-month revenue $29.1M (+31% YoY).
BASF sues Nanophase over exclusivity breach; Nanophase files counterclaim for declaratory judgment
BASF filed complaint in NJ Superior Court alleging breach of exclusivity provisions in Zinc Oxide Supply Agreement.
Nanophase reports record Q2 2022 revenue of $11.2M, up 58% YoY; Solésence revenue up 58%
Q2 revenue $11.2M, a record, up 58% from $7.1M in Q2 2021.
Nanophase reports record Q1 revenue of $8.2M, up 15% YoY; guides to >$40M for FY2022
Q1 revenue $8.2M vs $7.1M prior year (+15%); Solésence revenue $5.6M (+29% YoY).
Nanophase posts record FY2021 revenue $29.5M, up 70% YoY; Q4 net loss $0.4M
FY2021 revenue $29.5M (70% YoY growth); net income $2.3M ($0.05/sh) vs $1.0M ($0.03) in 2020.
A/R Revolver facility limit raised from $6M to $8M; new Inventory facility of up to $4M added
Lease term from Dec 31, 2021 to May 31, 2032; Premises expandable to 260,890 sq ft on Nov 1, 2022.
Nanophase Q3 revenue $7.9M up 80% YoY; nine-month net income $2.7M
Q3 revenue $7.9M vs $3.9M YoY; nine-month revenue $22.1M vs $12.3M.
Record Q2 revenue $7.1M vs $4.3M in Q2 2020 (YoY +65%).
Nanophase restates Q1 2021 financials over PPP loan forgiveness timing; cites material weakness
Board determined Q1 2021 10-Q requires restatement to reflect PPP loan forgiveness; original filing no longer reliable.
Effective April 24, 2026, the Board of Directors of the Company (the "Board") appointed Marc James to serve as a Class II Director of the Board for the remainder of the term of Class II Directors of the Board, expiring at the 2026 Annual Meeting of Shareholders of the Company.
On July 19, 2023, Mr. Mark E. Miller was appointed as a member of the Board of Directors (the “Board”) of Nanophase Technologies Corporation (the “Company”).
Max materiality 0.85 · Median 0.65 · Most common event earnings